BMT CTN PROTOCOL 1302, Multicenter Phase II, Double Blind, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma March 15, 2018 Type of Cancer Multiple Myeloma Sponsor NMDP BMT Protocol Number NMDP BMT CTN 1302 To Learn More Call 201-510-0910
